Table 5.
Complications of HIVEC treatment with mitomycin C [Group A] (75 patients) and epirubicin [Group B] (28 patients)
| Grade | Group A, N (%) | Group B, N (%) | p value | |
|---|---|---|---|---|
| Facial swelling | 1 | 1/75 (1.33%) | 1/28 (3.57%) | .9441 |
| Facial swelling* | 2 | 1/75 (1.33%) | 0/28 (0%) | .6063 |
| Hand urticaria | 1 | 2/75 (2.67%) | 1/28 (3.57%) | .6777 |
| Total body urticaria* | 2 | 0/75 (0%) | 1/28 (3.57%) | .6063 |
| Bladder spasm | 1 | 3/75 (4%) | 1/28 (3.57%) | .6362 |
| Frequency/urgency | 1 | 3/75 (4%) | 1/28 (3.57%) | .6362 |
| Frequency/urgency | 2 | 2/75 (2.67%) | 1/28 (3.57%) | .6777 |
| Frequency/urgency | 3 | 2/75 (2.67%) | 5/28 (17.86%) | .0064 |
| Urinary tract pain | 1 | 4/75 (5.33%) | 2/28 (7.14%) | .9014 |
| Urinary tract pain | 2 | 3/75 (4%) | 1/28 (3.57%) | .6362 |
| Urinary tract pain* | 3 | 2/75 (2.67%) | 1/28 (3.57%) | .6777 |
| Abdominal pain | 1 | 1/75 (1.33%) | 1/28 (3.57%) | .9441 |
| Haematuria | 1 | 1/75 (1.33%) | 0/28 (0%) | .6063 |
| Overall complications | 25/75 (33.3%) | 16/28 (57.14%) | .0488 | |
| *Therapy discontinuation | 3/75 (4%) | 2/28 (7.14%) | .8847 |
HIVEC – hyperthermic intravesical chemotherapy